Brief introduction of 5308-25-8

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5308-25-8,1-Ethylpiperazine,as a common compound, the synthetic route is as follows.

1-Ethyl-4-(3-nitro-phenyl)-piperazineA mixture of 1-fiuoro-3-nitrobenzene (3.2 mL, 29.7 mmol) and N-ethyl-piperazine (7.6 mL, 59.4 mmol, 2 equiv) is heated to reflux and stirred for 117h. The reaction mixture is allowed to cool to RT and diluted with H2O (40 mL) and DCM/MeOH (9:1 , 80 mL). The aqueous layer is separated and extracted with DCM/MeOH (9:1). The organic phase is washed with brine, dried (Na2SO4), filtered and concentrated. Purification of the crude product by silica gel column chromatography (DCM/MeOH, 1 :0 ? 95:5) affords the title compound as a brown oil: ESI-MS: 236.0 [MH]+; tR= 2.49 min (purity: 99%, system 1 ); TLC: R, – 0.26 (DCM/MeOH, 95:5)., 5308-25-8

The synthetic route of 5308-25-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; NOVARTIS AG; NOVARTIS PHARMA GmbH; WO2007/71752; (2007); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics